Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28523847 | 1.00 | DPP4 (0.33) | DPP4FFAR3PREPFAPDPP8 | |
| SCHEMBL967589 | 0.84 | ALDH1A1 (0.36) | DPP4FFAR3 | |
| Hydrochloric Acid SCHEMBL6026725 | 0.82 | ALDH1A1 (0.35) | DPP4FFAR3 | |
| SCHEMBL15665598 | 0.82 | ALDH1A1 (0.34) | DPP4FFAR3 | |
| SCHEMBL22965030 | 0.80 | MME (0.39) | DPP4F2 | |
| SCHEMBL11040604 | 0.79 | FFAR3 (0.34) | DPP4FFAR3 | |
| SCHEMBL22964983 | 0.79 | DPP4 (0.35) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL11603642 | 0.79 | ACE (0.36) | — | |
| SCHEMBL8253658 | 0.79 | GAA (0.43) | — | |
| SCHEMBL4326048 | 0.79 | ACE (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112423774-A | Therapeutic compositions and methods of use for treating mild cognitive impairment, depression and psychological disorders | L·H·L·特兰 | 2021-02-26 | — | — | CN | claimed |
| EP-1888618-A4 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-15 | — | — | EP | claimed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | claimed |
| EP-1888618-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | Neuren Pharmaceuticals Limited (NZ) | 2008-02-20 | — | — | EP | claimed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | claimed |
| CN-112423774-A | Therapeutic compositions and methods of use for treating mild cognitive impairment, depression and psychological disorders | L·H·L·特兰 | 2021-02-26 | — | — | CN | disclosed |
| WO-2014085480-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | DPP4 286/4885FFAR3 2136/4885PREP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.